Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon13 and 7 bp deletion in exon13.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ITGA11, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ITGA11 also known as Integrin alpha-11 functions mechanically as an alpha subunit that combines with the beta-1 subunit to form a collagen receptor integrin complex. The protein has a mass of approximately 135 kDa and its expression occurs mainly in fibroblastic cells located within connective tissue including areas like skin and lungs. ITGA11 plays a role in cell adhesion helping mediate interactions between cells and the extracellular matrix which is essential for tissue structure and function.
Biological function summary
ITGA11 influences various cellular processes including cell migration proliferation and differentiation. The protein is part of the alpha-11 beta-1 integrin complex that specifically binds to interstitial collagens. This interaction allows ITGA11 to facilitate communication signals that control cellular behavior. Its effective function in collagen recognition establishes ITGA11 as important for maintaining the structural integrity and repair of tissues particularly during injury or developmental processes.
Pathways
ITGA11 integrates into the collagen-mediated signaling pathway which connects to cellular responses to the extracellular matrix. In particular ITGA11 interacts with other proteins like integrin beta-1 to affect cell survival and movement. Another important pathway involving ITGA11 is the TGF-beta signaling pathway where it contributes to matrix reorganization and fibroblast activation both significant in tissue development and repair mechanisms.
ITGA11 shows association with fibrotic diseases and certain cancers. In fibrosis excessive collagen deposition occurs and ITGA11's interaction with collagen and its regulatory role in fibroblasts can exacerbate this condition. This relationship links ITGA11 to proteins like integrin beta-1 and TGF-beta which are involved in fibrotic tissue transformation. In cancer ITGA11 supports tumor stroma formation contributing to cancer cell survival and spread emphasizing its importance in tumor biology and as a potential therapeutic target.
